<- Go home

Added to YB: 2024-03-01

Pitch date: 2024-02-02

NTRA [bullish]

Natera, Inc.

+240.24%

current return

Author Info

No bio for this author

Company Info

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Market Cap

$28.2B

Pitch Price

$67.13

Price Target

N/A

Dividend

N/A

EV/EBITDA

-91.38

P/E

-89.19

EV/Sales

12.92

Sector

Biotechnology

Category

growth

Show full summary:
RiverPark/Next Century Growth Fund New Position: Natera, Inc.

$NTRA: Leader in cell-free DNA tests for oncology, women's & organ health. Signatera addresses min residual disease in cancer. Consistent rev growth, nearing positive cash flow after years of investment. Aims to integrate personalized genetic testing into standard of care.

Read full article (1 min)